• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从一名急性淋巴细胞白血病患者建立B细胞系并进行鉴定。

Establishment and characterization of a B-cell line from a patient with acute lymphoblastic leukemia.

作者信息

Kottaridis S, Perez S, Kokkinopoulos D, Delinassios J G, Pangalis G A, Cosmidis H, Goula I, Papamichail M

出版信息

Leuk Res. 1985;9(1):113-22. doi: 10.1016/0145-2126(85)90025-6.

DOI:10.1016/0145-2126(85)90025-6
PMID:3872970
Abstract

A permanent lymphoblastoid cell line was established from the peripheral blood of a child with acute lymphoblastic leukemia. The cell line, designated SDK, grows in a stationary suspension culture, forming aggregates, in RPMI medium supplemented with 10% FCS, with a doubling time of 50-60 h. Immunologic markers and cytological features suggested that the SDK cells should be identified as being of B-cell origin. The cells failed to form rosettes with sheep erythrocytes, did not express T-cell antigens as defined by monoclonal antibodies, and exhibited surface and cytoplasmic immunoglobulin determinants. Chromosome analysis revealed the presence of three cell populations with (a) 46XY; (b) t(8q-; 14q+) or 2p-; 14q+) and (c) cells with unidentifiable markers. SDK demonstrated susceptibility to TPA-induced differentiation toward plasma cells.

摘要

从一名急性淋巴细胞白血病患儿的外周血中建立了一个永久性淋巴母细胞系。该细胞系命名为SDK,在添加10%胎牛血清的RPMI培养基中,以固定悬浮培养方式生长,形成聚集体,倍增时间为50 - 60小时。免疫标记和细胞学特征表明,SDK细胞应被鉴定为B细胞起源。这些细胞不能与绵羊红细胞形成玫瑰花结,不表达单克隆抗体所定义的T细胞抗原,并且表现出表面和细胞质免疫球蛋白决定簇。染色体分析显示存在三个细胞群体,(a) 46XY;(b) t(8q-; 14q+)或2p-; 14q+)以及(c)具有无法识别标记的细胞。SDK显示出对TPA诱导向浆细胞分化的敏感性。

相似文献

1
Establishment and characterization of a B-cell line from a patient with acute lymphoblastic leukemia.从一名急性淋巴细胞白血病患者建立B细胞系并进行鉴定。
Leuk Res. 1985;9(1):113-22. doi: 10.1016/0145-2126(85)90025-6.
2
Different stages of B cell differentiation in non-T acute lymphoblastic leukemia.非T细胞急性淋巴细胞白血病中B细胞分化的不同阶段
J Clin Invest. 1984 Nov;74(5):1756-63. doi: 10.1172/JCI111594.
3
Establishment and cytological characteristics of two in vitro T-cell lines derived from a child with acute lymphatic leukemia and a man with adult T-cell leukemia in Japan.源自日本一名急性淋巴细胞白血病儿童和一名成人T细胞白血病男性的两株体外T细胞系的建立及其细胞学特征
Int J Cancer. 1982 Aug 15;30(2):173-80. doi: 10.1002/ijc.2910300208.
4
Immunologic, morphologic and chromosomal characterization of a cell line (TC78) established from a child with acute lymphoblastic leukemia.从一名急性淋巴细胞白血病患儿建立的细胞系(TC78)的免疫学、形态学及染色体特征
Leuk Res. 1985;9(12):1497-506. doi: 10.1016/0145-2126(85)90042-6.
5
Heterogeneity of childhood acute lymphoblastic leukemia--impact on prognosis and therapy.儿童急性淋巴细胞白血病的异质性——对预后和治疗的影响
Semin Oncol. 1985 Sep;12(3):268-80.
6
Differentiation of human myeloid leukemia cell lines induced by tumor-promoting phorbol ester (TPA). I. Changes of the morphology, cytochemistry and the surface differentiation antigens analyzed with monoclonal antibodies.促肿瘤佛波酯(TPA)诱导人髓系白血病细胞系的分化。I. 用单克隆抗体分析形态学、细胞化学及表面分化抗原的变化。
Neoplasma. 1983;30(3):257-72.
7
A non-T, non-B human leukemia cell line (NALM-1): establishment of the cell line and presence of leukemia-associated antigens.一种非T、非B人类白血病细胞系(NALM-1):细胞系的建立及白血病相关抗原的存在
J Natl Cancer Inst. 1977 Jul;59(1):83-7. doi: 10.1093/jnci/59.1.83.
8
Establishment of an Epstein-Barr virus-determined nuclear antigen-negative human B-cell line from acute lymphoblastic leukemia.从急性淋巴细胞白血病建立爱泼斯坦-巴尔病毒决定的核抗原阴性人B细胞系。
J Natl Cancer Inst. 1977 Jul;59(1):93-4. doi: 10.1093/jnci/59.1.93.
9
Cytogenetic and immunoglobulin markers of human leukemic B-cell lines.人白血病B细胞系的细胞遗传学和免疫球蛋白标志物
Cancer Res. 1977 Sep;37(9):3096-9.
10
Establishment and characterization of a human EBV-negative B cell line (MN 60).
Leuk Res. 1982;6(5):685-93. doi: 10.1016/0145-2126(82)90085-6.